AUA, others comment on new USPSTF draft on screening for risk of prostate cancer

The American Urological Association (AUA), along with other organizations, issued a statement yesterday regarding their reactions to the new, draft guidance issues by the U.S. Preventive Services Task Force (USPSTF). … READ MORE …

Genomic prediction of risk for biochemical relapse post-surgery

Yet another genetic/genomic test (this one developed by Metamark Genetics) may have value in the assessment of risk for biochemical progression after first-line surgery for prostate cancer. … READ MORE …

USPSTF changes guidance on testing for risk of prostate cancer

As yet we have not seen the details, but, according to a report on National Public Radio early this morning, the US Preventive Services Task Force (USPSTF) has stated that men up to age 70 should discuss the risk and benefits of PSA testing with their doctors and then make individual decisions about whether to get tested. … READ MORE …

Active surveillance in men with higher-risk forms of localized prostate cancer

The abstract of a paper currently in press in the Journal of Urology has offered us some potentially fascinating insight into the comparative outcomes of patients with low- and higher-risk forms of localized prostate cancer when they are initially managed on active surveillance. … READ MORE …

Getting closer to diagnosing prostate cancer “by a sniff test”

Yet another research group is presenting data this week (at a meeting of the American Chemical Society) on the potential to identify risk for prostate cancer based on smell. … READ MORE ….

Might prostate cancer be a sleep deprivation-related disorder?

According to a report on a presentation given yesterday at an ongoing meeting in Washington, DC, “Adequate sleep isn’t a luxury; it’s essential. And for men, it might even mean the difference between life and death”. … READ MORE …

Revised ASCO/CCO brachytherapy guidelines

The publication of the ASCENDE-RT clinical trial (discussed here) has led to a revision in the brachytherapy guidelines (available here) issued jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO). The guidelines are for patients who choose radical therapy rather than active surveillance. … READ MORE …